Postoperative Residual Paralysis-What it is, How to Recognize it, and How to Treat it: Evidence-based Summary

Area of Science:

• Anesthesiology and Perioperative Medicine
• Pharmacology
• Patient Safety

Background:

• Postoperative residual paralysis (PRP) is a significant concern following anesthesia.
• It can lead to adverse respiratory events and prolonged recovery.
• Effective management strategies are essential to mitigate risks.

Purpose of the Study:

• To synthesize current evidence on the definition, recognition, and management of PRP.
• To compare the efficacy of different reversal agents and monitoring techniques.
• To provide evidence-based recommendations for clinical practice.

Main Methods:

• Comprehensive literature search across major databases (PubMed, Embase, CINAHL).
• Inclusion of high-quality evidence: guidelines, systematic reviews, meta-analyses, RCTs, and expert consensus.
• Quality assessment using Cochrane RoB2 and Johns Hopkins Evidence-based Model.

Main Results:

• Sugammadex demonstrated superior efficacy in reducing PRP incidence versus neostigmine.
• Sugammadex accelerated recovery of muscle strength and train-of-four ratio.
• Quantitative neuromuscular monitoring proved more reliable than qualitative methods.

Conclusions:

• Sugammadex offers a more efficient reversal of neuromuscular blockade compared to neostigmine.
• Administering reversal agents and using quantitative monitoring are key to preventing PRP.
• While sugammadex improves reversal, its impact on overall pulmonary complications requires further investigation.